GB0111279D0 - Radiolabelled liposomes - Google Patents

Radiolabelled liposomes

Info

Publication number
GB0111279D0
GB0111279D0 GBGB0111279.6A GB0111279A GB0111279D0 GB 0111279 D0 GB0111279 D0 GB 0111279D0 GB 0111279 A GB0111279 A GB 0111279A GB 0111279 D0 GB0111279 D0 GB 0111279D0
Authority
GB
United Kingdom
Prior art keywords
liposomes
internalised
internalisation
entrapped
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0111279.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Priority to GBGB0111279.6A priority Critical patent/GB0111279D0/en
Publication of GB0111279D0 publication Critical patent/GB0111279D0/en
Priority to US10/477,157 priority patent/US20040170560A1/en
Priority to ES02769160T priority patent/ES2323493T3/es
Priority to PCT/GB2002/002100 priority patent/WO2002089771A1/en
Priority to AT02769160T priority patent/ATE430557T1/de
Priority to DE60232237T priority patent/DE60232237D1/de
Priority to EP02769160A priority patent/EP1385480B1/en
Priority to JP2002586908A priority patent/JP4629308B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
GBGB0111279.6A 2001-05-10 2001-05-10 Radiolabelled liposomes Ceased GB0111279D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0111279.6A GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes
US10/477,157 US20040170560A1 (en) 2001-05-10 2002-05-10 Liposomes
ES02769160T ES2323493T3 (es) 2001-05-10 2002-05-10 Liposomas.
PCT/GB2002/002100 WO2002089771A1 (en) 2001-05-10 2002-05-10 Liposomes
AT02769160T ATE430557T1 (de) 2001-05-10 2002-05-10 Liposomen
DE60232237T DE60232237D1 (de) 2001-05-10 2002-05-10 Liposomen
EP02769160A EP1385480B1 (en) 2001-05-10 2002-05-10 Liposomes
JP2002586908A JP4629308B2 (ja) 2001-05-10 2002-05-10 リポソーム

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111279.6A GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes

Publications (1)

Publication Number Publication Date
GB0111279D0 true GB0111279D0 (en) 2001-06-27

Family

ID=9914262

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0111279.6A Ceased GB0111279D0 (en) 2001-05-10 2001-05-10 Radiolabelled liposomes

Country Status (8)

Country Link
US (1) US20040170560A1 (https=)
EP (1) EP1385480B1 (https=)
JP (1) JP4629308B2 (https=)
AT (1) ATE430557T1 (https=)
DE (1) DE60232237D1 (https=)
ES (1) ES2323493T3 (https=)
GB (1) GB0111279D0 (https=)
WO (1) WO2002089771A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101133084B1 (ko) * 2002-12-31 2012-04-04 자이더스 비에스브이 파마 프라이빗 리미티드 장기간 순환성 비-페길레이티드 리포좀
DE602004027655D1 (de) * 2003-11-03 2010-07-22 Yissum Res Dev Co Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
EP3415151A1 (en) * 2008-05-23 2018-12-19 The University of British Columbia Modified drugs for use in liposomal nanoparticles
CA2746527A1 (en) * 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN105168135A (zh) * 2010-03-12 2015-12-23 博格有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
BR112013027413A2 (pt) * 2011-04-26 2019-09-24 Cedars Sinai Medical Center vancomicina lipossomal para o tratamento de infecções de sarm.
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015023797A1 (en) * 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CA2963931A1 (en) 2014-10-06 2016-04-14 Exicure, Inc. Anti-tnf compounds
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
CN105434368A (zh) * 2014-11-27 2016-03-30 广州白云山明兴制药有限公司 一种注射用还原型谷胱甘肽及其预冻方法
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
JP2020526558A (ja) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6137735A (ja) * 1984-07-31 1986-02-22 Terumo Corp ヘモグロビン含有リポソ−ムおよびその製造方法
DE69018460T2 (de) * 1989-04-18 1995-11-09 Vestar Inc Markierung mit liposomen von ischämischen geweben.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5143713A (en) * 1990-05-30 1992-09-01 Board Of Regents, The University Of Texas System 99m Tc labeled liposomes
AU3244393A (en) * 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
JPH11171772A (ja) * 1997-12-11 1999-06-29 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
MXPA01010977A (es) * 1999-04-29 2002-07-22 Alza Corp Composiciones de liposoma para la retencion mejorada del medicamento.
CA2340757A1 (en) * 1999-07-07 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Delivery of liposomal-encapsulated antioxidants and applications thereof

Also Published As

Publication number Publication date
JP4629308B2 (ja) 2011-02-09
ES2323493T3 (es) 2009-07-17
US20040170560A1 (en) 2004-09-02
EP1385480A1 (en) 2004-02-04
WO2002089771A1 (en) 2002-11-14
EP1385480B1 (en) 2009-05-06
JP2004529163A (ja) 2004-09-24
ATE430557T1 (de) 2009-05-15
DE60232237D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
GB0111279D0 (en) Radiolabelled liposomes
PL344715A1 (en) Fixed oral dose composition featured by prolonged release of active substance
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
HUP9901199A3 (en) Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds
AU6011701A (en) Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
ATE321537T1 (de) Pharmazeutische zubereitung enthaltend doxazosin
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
HUP9802865A3 (en) N-(substituted phenyl)-pyrazole-derivatives, preparation and use thereof, parasiticidal compositions containing these compounds as active ingredients
WO2002045769A3 (en) A bilayer structure which encapsulates multiple containment units and uses thereof
DE60112756D1 (de) Racecadotril enthaltende trockene pulverformulierung
ES2161292T3 (es) Composicion de higiene oral.
AP2004003045A0 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same.
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
AU1093301A (en) Film forming composition containing octyl benzoate
WO2002048142A1 (en) Medicinal compositions having improved absorbability
SE9802937D0 (sv) Novel compounds
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
TW200509863A (en) Irradiation device for medical use
GB9907571D0 (en) Compounds
BR1100143A (pt) Composto, e, composição farmacêutica.
EP0863192A4 (en) HUMIDIFIER COMPOSITION, THIS CONTAINING BASE COMPOSITION AND COSMETIC MATERIAL OR EXTERNAL APPLICATION WHICH CONTAINS THIS HUMIDIFIER COMPOSITION
FI931966A7 (fi) Kalvoa muodostavia materiaaleja sisältäviä röntgenvarjoainekoostumuksia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)